A biopharmaceutical company focused on the development and commercialization of products designed to treat respiratory, inflammatory and critical care diseases linked to the body's inflammatory response.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
My old college dorm was voted "Most apathetic" in a student survey, so we all got T-shirts that said "Everyone says we're apathetic, but we don't care." That's pretty much how I feel about Cornerstone. I care just enough to drop a green thumb and a pitch.
Cornerstone is a good candidate for a rebound if broad market parameters improve. Revenues have been stable and the bottom line will benefit from sales of Spectracef and Factive. Impending approval of generic Tussionex may provide another boost. CAPS only, 5-10 points and out.